Losartan Potassium Tablet
Product Images NDC 68788-4160

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68788-4160). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan Potassium Tab Usp 50mg (62207 742 03)

The label for Losartan Potassium Tablets USP 50 mg features the product name prominently in black on a yellow background. It indicates the tablet form with a 50 mg strength, generic for Cozaar. Manufacturer information shows Granules India Limited. The label includes dosage instructions in English and Spanish, barcodes, and a warning with storage conditions. Batch, expiration date, and lot number fields are present but blank.*

FDA Label Image

Fig-1 (Fig 1)

A line graph comparing the percentage of patients with the primary endpoint over time between Atenolol and Losartan potassium groups during a study lasting up to 66 months. The graph includes a note on adjusted risk reduction of 13% with p=0.021.*

FDA Label Image

Fig-2 (Fig 2)

A line graph comparing the percentage of patients with fatal or non-fatal strokes over 66 months between Atenolol (dashed line) and Losartan Potassium (solid line). The graph indicates an adjusted risk reduction of 25% for Losartan Potassium, with a p-value of 0.001.*

FDA Label Image

Fig-3 (Fig 3)

A forest plot comparing hazard ratios of Losartan Potassium versus Atenolol in two categories: Primary Composite and Stroke (Fatal/Non-fatal). The plot displays hazard ratios with 95% confidence intervals across subgroups based on overall results, age, gender, race, ISH, diabetes, and cardiovascular disease history. Each subgroup includes patient counts and event rates for both drugs, showing which treatment is favored within each category.*

FDA Label Image

Losartan-figure4-jpg (Losartan Figure4 Jpg)

A Kaplan-Meier survival curve chart showing the percentage of patients experiencing an event over 48 months. It compares Losartan potassium (solid line) and placebo (dotted line), indicating a risk reduction of 16.1% with Losartan potassium and a p-value of 0.022.*

FDA Label Image

Losartan-structure-jpg (Losartan Structure Jpg)

Chemical structure of Losartan potassium depicting its molecular arrangement, including the potassium ion (K+). The diagram shows interconnected rings and functional groups characteristic of Losartan.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.